Mergers & Acquisitions

Found 20,851 articles

• Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici

  3/22/2023

  Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici.

• Bionoid Pharma Announces Letter of Intent to Acquire Global Alerts Corp.

  3/22/2023

  Bionoid Pharma, Inc. announced today that it has signed a Letter of Intent to acquire all the outstanding shares of Global Alerts Corp.

• Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

  3/21/2023

  Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome.

• Ally Biotech Announces Acquisition of Popular THC “Chill Pill” Soft Gel Cap Line From Desert Medical Campus, Inc.

  3/21/2023

  Ally Biotech, a science-based company and provider of leading-edge bioactive cannabinoid delivery solutions, today announced the acquisition of the popular Chill Pill™ brand, an extensive line of soft, easy-to-swallow soft gel caps and all of its assets, from Desert Medical Campus, in an all-cash transaction.

• Casi Pharmaceuticals Completes Redomiciliation Merger

  3/21/2023

  CASI Pharmaceuticals, Inc. announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company has been completed.

• Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

  3/21/2023

  Zura Bio Limited announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company, on March 20, 2023.

• Quest Diagnostics Completes Acquisition of Northern Light Laboratory in Maine

  3/20/2023

  Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of Northern Light Laboratory, the outreach laboratory services business of Northern Light Health, a large integrated healthcare system in Maine.

• INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute

  3/20/2023

  INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has signed binding agreements to acquire Wisconsin Fertility Institute.

• CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

  3/20/2023

  CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc.

• GENETWORx Looking to acquire or partner with Diagnostic Laboratories

  3/17/2023

  GENETWORx, a private equity backed laboratory, announces it’s looking to buy or partner with other diagnostics laboratories.

• Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp

  3/16/2023

  Enzo Biochem, Inc. announced that it has entered into an agreement for Labcorp to acquire the assets of Enzo’s Clinical Laboratory division.

• 

  Concentra's Buy Offer May Jeopardize Jounce's Merger with Redx

  3/15/2023

  Jounce Therapeutics has received an unsolicited and non-binding acquisition proposal from Concentra Biosciences, looking to buy 100% of Jounce's equity at a per-share price of $1.80 in cash.

• Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

  3/15/2023

  Statera Biopharma, Inc. is pleased to announce it has entered into a non-binding letter of intent with Worksite Labs, Inc., setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL.

• Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

  3/15/2023

  Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of rare disease product candidate ET-600 from Tulex Pharmaceuticals.

• Werfen Completes Acquisition of Immucor, Inc., Expanding Leadership in Specialized Diagnostics

  3/15/2023

  Werfen announced that it has successfully completed the acquisition of Immucor, Inc., after obtaining all necessary regulatory and antitrust approvals.

• Miltenyi Biotec acquires biosensor company lino Biotech

  3/15/2023

  lino Biotech announced it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.

• HeartBeam Announces Acquisition of LIVMOR Assets

  3/14/2023

  HeartBeam, Inc. (NASDAQ: BEAT) today announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers.

• Miravo Healthcare™ and Searchlight Pharma Inc. Announce Closing of Arrangement

  3/14/2023

  Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“Miravo” or the “Company”) and Searchlight Pharma Inc., a private Canadian-based specialty healthcare company (“Searchlight”), are pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) of Miravo with Searchlight.

• ADAMA Acquiring the Remaining Stakes of its Bio Stimulants Business in Chile

  3/14/2023

  ADAMA Ltd., a leading crop protection company, announced that it has exercised its call option to acquire the remaining 40% stake in ADAMA Chile, formerly known as Chile Agro.

• 

  Pfizer Wins Seagen Sweepstakes with $43B Bid

  3/13/2023

  Pfizer will acquire the Seattle-based antibody-drug conjugate leader in a $43 billion deal expected to close late in 2023 or early 2024.